Remus Pharmaceuticals Limited (NSE: REMUS) is an Ahmedabad, Gujarat-based company in the Pharmaceutical Product Distribution industry. With a market capitalisation of ₹941 Cr, it ranks #1,623 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 13 in Pharmaceutical Product Distribution. At ₹820.00 (as of 16 Nov 2026), the share price is 21.1% below its 52-week high of ₹1,039.00 and 41.4% above its 52-week low of ₹580.00. The share price is up 0.6% over one year and down 7.7% over three months.
| Current Price | ₹820.00 |
|---|---|
| Market Cap | ₹941 Cr |
| NSE Symbol | REMUS |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Distributors > Pharmaceutical Product Distribution |
| P/E Ratio | 26.1 |
| Return on Equity | 13.78% |
| Return on Assets | 6.67% |
| 52-Week Range | ₹580.00 – ₹1,039.00 |
| 1-Year Price Change | +0.6% |
| 3-Month Price Change | -7.7% |
| Beta (1Y) | 0.54 |
| Dividend Yield | 0.12% |
| Headquarters | Ahmedabad, Gujarat |
| Website | remuspharma.com |
Promoters held 70.95% of Remus Pharmaceuticals Limited's shares as of Sept 2026, against 70.91% in Sept 2025 (+0.04 percentage points).
Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceuticals products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company offers tablet, hard and soft gelatine capsules, liquid and lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays and solutions, eye drops, creams, gels, ointments, suspensions, oral solutions and suspensions, sachets, and ophthalmic and other dosage forms. It also exports its products. Remus Pharmaceuticals Limited was incorporated in 2015 and is based in Ahmedabad, India.
1. Pharmaceutical-This segment engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceutical-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Entero Healthcare Solutions Limited | ₹8,733 Cr | 74.6 | 8.28% | ₹2,087 Cr | +80.7% |
| Remus Pharmaceuticals Limited | ₹941 Cr | 26.1 | 13.78% | — | +0.6% |
| Health X Platform Limited (Sastasundar Ventures Ltd) | ₹871 Cr | 752.7 | -0.18% | ₹484 Cr | -5.7% |
| Aptus Pharma Limited | ₹837 Cr | 156.8 | — | — | +754.0% |
| Vasa Denticity Limited | ₹797 Cr | 76.5 | 6.68% | ₹87 Cr | -21.4% |
| Bijoy Hans Ltd | ₹523 Cr | — | — | — | +128.4% |
| Speciality Medicines Limited | ₹149 Cr | 11.5 | — | — | — |
| Vijaypd Ceutical Limited | ₹136 Cr | 23 | 9.53% | — | — |
| Royal Sense Limited | ₹39 Cr | 5.6 | — | — | -71.2% |
Listed by market capitalisation. Ratios are shown for context only.
Remus Pharmaceuticals Limited is trading at ₹820.00, with a market capitalisation of ₹941 Cr.
Remus Pharmaceuticals Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors > Pharmaceutical Product Distribution).
Remus Pharmaceuticals Limited has a P/E of 26.1 and a return on equity of 13.78%.
Remus Pharmaceuticals Limited is listed on the NSE under the symbol REMUS.
Remus Pharmaceuticals Limited's share price is up 0.6% over one year and down 7.7% over three months. Its 52-week range is ₹580.00 to ₹1,039.00.
Promoters held 70.95% of Remus Pharmaceuticals Limited's shares as of Sept 2026, against 70.91% in Sept 2025 (+0.04 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.